

**SPEAKER 1:** So we now know in 2018 that we can talk about three S's describing what's truly unique about this therapy, first it's selectivity for the cells that cause either a malignancy like cutaneous T-cell lymphoma, or on the other side of the immune coin, the cells that are required for severe, what are reactive immunologic problems. So the first is selectivity. The second was the astonishing safety, and that's held.

Unlike other potent therapies, I'm not aware at least in my own extensive experience, and from cases I've heard about throughout the world, I'm not aware of patients who have responded to this therapy well who have had to stop it because of limiting, adverse reactions. That's almost unbelievable in terms of the safety profile. So safety is the second S.

The third is symmetry. I'm not aware of, and I ask every audience to whom I speak about this that are generally very sophisticated, can anybody think of another disease, another immunotherapeutic agent that can be prescribed that works on both sides of the immune coin, immunizing when needed against a cancer, and tolerizing when needed against an autoreactive set of T-cells causing themselves serious disease. So we're talking about special, patient specific, cancer specific selectivity, an extraordinary safety profile, and symmetry of efficacy.